Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled, “Discovery of microRNAs and other small RNAs in solid tumors,” in the online edition of Nucleic Acid Research.
"Our discovery of these new microRNAs gives us direct and exclusive access to 49 novel microRNAs, each one of which has the potential to be, alone or in combination with other microRNAs, a diagnostic biomarker, response biomarker or drug target. In addition, we have filed patent applications on each of these newly discovered microRNAs to enhance our expanding IP portfolio,” stated Kenneth A. Berlin, President and CEO of Rosetta Genomics.
“So far this year, we have had six peer-reviewed articles published on our microRNA technology. These publications are a further demonstration of how Rosetta Genomics is maintaining a leadership position in the development of microRNAs for personalized medicine applications.” The comprehensive database and proprietary technologies we have developed over the years are significant assets that allow us to lead in this area. They enable us to efficiently identify, extract, and quantify microRNAs, and transform them into commercially viable diagnostics, response biomarkers and therapeutics. This unrivaled set of capabilities allows us to harness the power of microRNAs as we work to improve healthcare worldwide,” added Mr. Berlin.